Study on Eribulin for Treating Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Sponsor: Massachusetts General Hospital

Sponsor score: 0

ClinicalTrials ID:NCT03331250

Provider View

This clinical trial is exploring the use of the drug Eribulin as a potential treatment for Angiosarcoma and Epithelioid Hemangioendothelioma (EHE).

Patient Parameters

Program Overview

This study is a Phase II clinical trial, which means it is testing the safety and effectiveness of Eribulin to see if it works for treating Angiosarcoma and EHE. Eribulin is not yet approved by the FDA for these specific cancers, but it is approved for other uses. The drug is designed to mimic a natural chemical from sea sponges and may help stop cancer cells from dividing, leading to their death.

Description

In this study, researchers are investigating how safe and effective Eribulin is for patients with Angiosarcoma or EHE. Eribulin works by blocking certain proteins in cancer cells, which may prevent them from dividing and cause them to die. This trial is important because it could lead to new treatment options for these rare cancers. Participants will receive Eribulin and be monitored for its effects on their cancer and overall health.

Eligibility Criteria

Inclusion Criteria

  • Have advanced Angiosarcoma or EHE that has spread or cannot be removed by surgery, and have tried at least one other treatment.
  • Up to 5 patients with EHE will be included.
  • Must provide a previous tumor sample for review.
  • Cancer must have progressed after previous treatment or during a period without treatment.
  • Must have measurable cancer that can be tracked using scans or exams.
  • Be over 18 years old.
  • Be in good overall health with a performance status of 0 to 2, meaning fully active or restricted in physically strenuous activity but ambulatory.
  • Have a life expectancy of more than 3 months.
  • Have normal blood and organ function based on specific tests.
  • Women of childbearing potential must use effective contraception during the study and for 4 months after.
  • Men must also use contraception during the study and for 4 months after.
  • Agree to have tumor biopsies before and during treatment.
  • Understand and agree to sign a consent form.

Exclusion Criteria

  • Have had recent chemotherapy, radiotherapy, or other cancer treatments within specified timeframes before starting the study.
  • Are currently taking other experimental drugs.
  • Have known brain metastases or cancer spread to the brain or spinal fluid.
  • Have a history of severe allergic reactions to similar drugs.
  • Have uncontrolled illnesses, such as active infections, heart failure, or recent heart attacks.
  • Are pregnant or breastfeeding.
  • Are HIV-positive and on antiretroviral therapy, due to potential drug interactions and increased risk of infections.

Locations

FACILITYZIPCITYSTATE
Massachusetts General Hospital02114BostonMassachusetts
Dana Farber Cancer Institute02115BostonMassachusetts

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.